Loading
A phase 1/2 trial of JDQ443, Trametinib, Cetuximab in non-small-cell lung cancer and small-cell lung cancer, run by Novartis Pharmaceuticals, now recruiting.
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments is a phase 1/2 interventional study registered as NCT07468071 by Novartis Pharmaceuticals, with 40 participants planned, started 2026-06-08 and due to reach its primary completion in 2029-06-11. Interventions recorded: Opnurasib, TNO155, trametinib, cetuximab, tislelizumab. Conditions listed: Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TNO155, JDQ443, Tislelizumab, Novartis.
Shares JDQ443, Trametinib, Cetuximab, Novartis.
Shares JDQ443, Novartis, Non-small-cell lung cancer.
Shares JDQ443, Novartis, Non-small-cell lung cancer.
Shares Trametinib, Tislelizumab, Novartis, Non-small-cell lung cancer.
Shares Tislelizumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Tislelizumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Tislelizumab, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/